key: cord-0737793-r084otwx authors: Rodino, K. G.; Peaper, D. R.; Kelly, B. J.; Bushman, F.; Marques, A.; Adhikari, H.; Jin Tu, Z.; Marrero Rolon, R.; Westblade, L. F.; Green, D.; Berry, G. J.; Wu, F.; Annavajhala, M. K.; Uhlemann, A.-C.; Parikh, B. A.; McMillen, T.; Jani, K.; Babady, N. E.; Hahn, A. M.; Koch, R. T.; Grubaugh, N. D.; Yale SARS-CoV-2 Genomic Surveillance Initiative,; Rhoads, D. D. title: Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1 date: 2022-04-28 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2022.04.25.22274187 sha: 7e14d5c3d2255a9900f9e1ef2cd0b2b5e139a1e0 doc_id: 737793 cord_uid: r084otwx Mutations in the viral genome of SARS-CoV-2 can impact the performance of molecular diagnostic assays. In some cases, such as S gene target failure, the impact can serve as a unique indicator of a particular SARS-CoV-2 variant and provide a method for rapid detection. Here we describe partial ORF1ab gene target failure (pOGTF) on the cobas(R) SARS-CoV-2 assays, defined by a [≥]2 thermocycles delay in detection of the ORF1ab gene compared to the E gene. We demonstrate that pOGTF is 97% sensitive and 99% specific for SARS-CoV-2 lineage BA.2.12.1, an emerging variant in the United States with spike L452Q and S704L mutations that may impact transmission, infectivity, and/or immune evasion. Increasing rates of pOGTF closely mirrored rates of BA.2.12.1 sequences uploaded to public databases, and, importantly increasing local rates of pOGTF also mirrored increasing overall test positivity. Use of pOGTF as a proxy for BA.2.12.1 provides faster tracking of the variant than whole-genome sequencing and can benefit laboratories without sequencing capabilities. Mutations in the primer/probe binding sites of the SARS-CoV-2 genome can impact oligonucleotide 59 binding and molecular test performance. Throughout the pandemic a number of such mutations have 60 been described, resulting in partial or complete PCR target failure (1). Mutations that impair diagnostic 61 detection is a criterion that the United States (US) Center for Disease Control and Prevention (CDC) 62 considers when classifying a novel SARS-CoV-2 lineage as a Variant of Concern (2). Most nucleic acid 63 amplification tests (NAAT) used for in vitro diagnostic (IVD) clinical testing and which have received 64 emergency use authorization (EUA) from the US Food and Drug Administration (FDA) employ multi-65 target assay design. This limits the diagnostic impact of a SARS-CoV-2 mutation that causes single-target 66 failure, as the additional primer/probe target sequences remain unaltered and adequately detect the 67 presence of viral nucleic acid. 68 Viral mutations can negatively impact assay performance, but these phenomena have proven useful 69 in certain situations. Whole-genome sequencing (WGS) of SARS-CoV-2 remains inadequately 70 brms package in R (13, 14) . Model parameters were established using CT value data collected across 138 seven platforms from March to June 2021, and the parameterized model was used to monitor for dEO 139 (and other target pair) outliers, with outliers identified as differences beyond the 99% posterior credible 140 interval of the expected CT value difference for the minimum CT value observed in the pair. Model code 141 and sample reproducible report are available at: https://github.com/bjklab/SARS-CoV-2_Ct_report. 142 At CCF, NGS sequencing libraries were prepared with Illumina COVIDSeq Test kit according to the 144 manufacture's recommendation. These libraries were sequenced paired end with read length 151 bases 145 using a NextSeq550 instrument (Illumina, San Diego, CA). Data analysis was performed with an in-house 146 developed bioinformatics pipeline. Sequence reads were mapped to reference genome Wuhan-Hu-1 147 (NC_045512.2) using BWA (version 0.7.15), variant calling was performed with both Freebayes (version 148 1.3.4) and LoFreq (version 2.1.5). Average coverage is x6567 and minimum coverage for mutation is x10. 149 Samples below this minimum coverage at the S gene codon 452 were considered unreliable, and these 150 genotypes were not considered in this study. Manual review of mutations was performed with 151 Integrative Genomics Viewer (IGV) to remove any artifacts. Variant classification was performed with 152 the Pangolin program (https://pangolin.cog-uk.io/ version v4.0.5, lineages version 2022-04-09). Derived 153 genomes with related information were deposited into GISAID database. Samples from (CUIMC) and 154 (WCMC) campuses were sequenced using the Oxford Nanopore (Oxford Nanopore Technologies, 155 Oxford, UK) Midnight protocol targeting 1200bp tiled amplicons across the length of the genome, as 156 previously described (15). Samples were sequenced on an Oxford Nanopore GridION using R9.4.1 flow 157 cells, with negative controls included on each run. Variant calling and consensus genome generation was 158 performed using the Oxford Nextflow ARTIC pipeline. Viral lineage classification, identification of 159 mutations, and phylogenetic analyses were performed using Pangolin v4.0.5 and Nextclade v1.11.0. 160 Genomic data from CUIMC is routinely uploaded to GISAID and to GenBank (under NCBI BioProject 161 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022. ; https://doi.org/10.1101 /2022 doi: medRxiv preprint PRJNA751551). At Yale, sequencing was performed as previously described, but Pangolin v4.0.5 was 162 used (16). All other SARS-CoV-2 WGS and lineage assignment was performed as previously described 163 (17) (18) (19) . 164 All charts and analyses were generated and performed with GraphPad Prism v8.2.1. Non-linear 166 regression of BA.2.12.1 and non-BA.2.12.1 was performed and best fit straight lines using the least 167 squares method and y-intercepts were compared for differences. Receiver operating characteristic 168 (ROC) curve to determine the performance characteristics of different dEO cut-off values was generated 169 by classifying samples with lineage information available as either "BA.2.12.1" or "Other". Positive and 170 negative predictive values of pOGTF for the detection of BA.2.12.1 were calculated using samples with 171 lineage information classified as either "BA.2.12.1" or "Other" where pOGTF was considered a dEO of ≥2 172 with an E-gene CT value ≤30. 173 All SARS-CoV-2 viral genomes have been deposited in GISAID and/or NCBI Genbank with accession 175 numbers or viral names listed in Table S1 . Table S1 ). Using an E gene CT value cutoff of ≤30 180 thermocycles to avoid non-specific variation between values near the limit of detection of the assay, an 181 outlier group with abnormal difference between the two CT values was identified. These data indicate 182 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 delayed detection of the ORF1ab target as compared to the E gene target. In total, 428 samples, run on 183 either the classic or combo SARS-CoV-2 assay, with pOGTF were detected during the study period. 184 Following institution-specific workflows for SARS-CoV-2 surveillance sequencing, a subset of samples 185 from the study period underwent WGS and lineage determination, including 71 samples showing pOGTF 186 (Table S1 ). Overwhelmingly, pOGTF samples were determined to be BA. We used the subset of samples with lineage information to generate an ROC curve to determine the 201 performance characteristics of different cut-off values for dEO (Figure 3 ). At a dEO cut-off of 2.1, the 202 sensitivity of was 97.2% while the specificity was 99.9% generated during the ROC analysis. After review 203 of the primary data, there was no difference in performance using a cutoff of 2.0 vs. 2.1, thus dEO ≥ 2.0 204 was selected for simplicity of use in identifying samples with pOGTF (Table 1) . When this criterion was 205 applied to our population of samples with lineage information with E gene CT values ≤30 the positive 206 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. values ≤30 and dEO ≥2 to define pOGTF, we reanalyzed our initial cobas SARS-CoV-2 results, finding that 208 the pOGTF group showed a mean dEO of 4.02 (95% CI 3.95 to 4.09) cycles as compared to -0.13 (95% CI -209 0.14 to -0.11) cycles in the non-pOGTF group (Table 2) . 210 To better understand the relationship between pOGTF, the emergence of BA.2.12.1, and overall test 211 positivity, we reviewed publicly available GISAID data to identify the number of all sequences and 212 BA.2.12.1 sequences uploaded from North America for the same time period as our study. Over a five-213 week period, the number of sequences submitted was stable, but the proportion of BA.2.12.1 samples 214 increased over time to approximately 13% of all sequences ( Figure 4A ). Our total testing data using the 215 pOGTF threshold also revealed, similar rise in samples demonstrating pOGTF, with the proportion of 216 positive samples with pOGTF steadily increasing over the study period, peaking in the final week of the 217 study (April 10-16) with a range from 11.1% to 39.8 % among the seven study sites ( Figure 4B ). This rise 218 is continuing. Importantly, the rise in pOGTF at our institutions has also corresponded to an increase in 219 overall test positivity, consistent with concerns of increased transmissibility of the BA.2.12.1 variant. 220 The role of CT values in clinical decision-making has been hotly debated throughout the pandemic; 222 however, studies have demonstrated their association with clinical outcomes and thus their potential to 223 inform clinical and logistic decisions (20-30). Nevertheless, multiple sources of pre-analytic and analytic 224 variability, along with the qualitative nature of SARS-CoV-2 assays, can complicate interpretation (31-225 33). However, with enough data points a normal dispersion between CT values of multi-target assays can 226 be constructed and monitored for evidence of abnormal differences in CT values between two targets 227 ( Figure 1) (6, 7) . Abnormal divergence between CT values may indicate polymorphisms that impact 228 detection of individual target genes, particularly when the values are well above the limit of detection 229 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The emergence of BA.2.12.1 at our study sites has coincided with increased positivity rates ( Figure 246 4), suggesting this variant is at least partially responsible for increased community transmission. 247 Increased transmissibility is likely attributable in part to the spike L452Q mutation present in BA.2.12.1, 248 which is not found in the parent strain but was present in Lambda (C.37). A similar mutation, L452R was 249 observed with Delta (B.1.617.2). L452Q has been implicated as an important driver of human 250 transmission, enhancing infectivity and receptor binding while reducing vaccine-derived immunity (35). 251 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For routine diagnostic laboratories, identifying mutations responsible for altering commercial assay 252 performance is hindered by a lack of public information regarding the primer/probe target regions of 253 commercially available FDA EUA assays. As stated during the July 26, 2021 CDC Clinical Laboratory 254 COVID-19 Response Call, "…ideally genomic regions targeted by IVDs would be made publicly available 255 by manufacturers, so prospective investigation of polymorphisms occurring within target regions could 256 be identified" (36). The authors support disclosure of primer/probe target regions for FDA EUA assays to 257 facilitate monitoring for mutations that could impact diagnostic assay performance. As in the case of 258 pOGTF with BA.2.12.1, two putative mutations (g.11674 C>T and g.15009 T>C) have been identified, but 259 the responsible mutation impacting the assay performance has not yet been confirmed. If the former, (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Other Lineage BA.2.12.1 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 28, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Endemic SARS-CoV-2 Polymorphisms Can Cause a Higher Emergence and expansion of 368 SARS-CoV-2 B.1.526 after identification in New York Grubaugh 372 ND. 2022. Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection 373 advantage over Delta in vaccinated persons SARS-CoV-2 Genomic Variation in Space and Time in Hospitalized 377 Patients in Philadelphia Severe Acute Respiratory Syndrome Coronavirus 2 Surveillance and Exposure 380 in the Perioperative Setting With Universal Testing and Personal Protective Equipment Policies Risk of Healthcare-Associated Transmission of SARS-CoV-2 in 384 Hospitalized Cancer Patients Can the Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase 386 Chain Reaction Cycle Threshold Value and Time From Symptom Onset to Testing Predict 387 Infectivity? Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain 389 Methods To Be Surrogates for Replication-Competent Virus To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value Predicting Infectious 394 Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples The Truth about SARS-CoV-2 Cycle Threshold Values Is Rarely Pure 397 and Never Simple Satlin 399 MJ. 2021. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of 400 Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease SARS-CoV-2 Viral Load Predicts Mortality in Patients with 405 and without Cancer Who Are Hospitalized with COVID-19 Prognostic Value of "Cycle Threshold" 409 in Confirmed COVID-19 Patients A Systematic Review of the Clinical Utility of 411 Cycle Threshold Values in the Context of COVID-19 Pretest Symptom Duration 414 and Cycle Threshold Values for Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-415 Transcription Polymerase Chain Reaction Predict Coronavirus Disease Infectious Diseases Society of America and Association for Molecular Pathology. 2021. IDSA and 421 AMP joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct) values for clinical 422 decision-making CoV-2 Cycle Threshold (CT) Values | AACC.org, on AACC The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune 434 resistance Genomic changes causing SARS-CoV-2 detection partial failure United States Food and Drug Administration, Drug. 2021. Establishing additional Conditions of 439 Authorization for the EUAs of Certain Molecular, Antigen and Serology IVDs related to viral 440 mutations Automated Real-Time Collection of Pathogen-Specific Diagnostic Data: 446 Syndromic Infectious Disease Epidemiology No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.